Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.

Oncotarget - 6 Oct 2015

Brady Anna K, McNeill Jonathan D, Judy Brendan, Bauml Joshua, Evans Tracey L, Cohen Roger B, Langer Corey, Vachani Anil, Aggarwal Charu

Abstract excerpt

INTRODUCTION: Mutations (MT) of the KRAS gene are the most common mutation in non-small cell lung cancer (NSCLC), seen in about 20-25% of all adenocarcinomas. Effect of KRAS MT on response to cytotoxic chemotherapy is unclear. METHODS: We undertook a single-institution retrospective analysis of 93 consecutive patients with stage IV NSCLC adenocarcinoma with known KRAS and EGFR MT status to determine the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Carboplatin

Share to Cisplatin

Share to Docetaxel

Share to Paclitaxel

Share to Taxoids

Source

Open in PubMed Open full text

Identifiers

PMID: 26471290
DOI: 10.18632/oncotarget.4711
PMCID: PMC4745798

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.PMID 26471290Read ↗

Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?Semantic proximity Read ↗

KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.Semantic proximity Read ↗

Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.Semantic proximity Read ↗

KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.Semantic proximity Read ↗

<i>KRAS</i>mutations impact clinical outcome in metastatic non-small cell lung cancerSemantic proximity Read ↗

KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non-small-cell Lung Cancer.Semantic proximity Read ↗

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.Semantic proximity Read ↗

The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

KRAS mutation: should we test for it, and does it matter?Semantic proximity Read ↗

KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.Semantic proximity Read ↗

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With ImmunotherapySemantic proximity Read ↗

KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.